Mad Money 01/05/26 | Audio Only

Mad Money - January 1, 2026: 2026 Game Plan & Market Analysis

Key Concepts:

• Long-Term Investing vs. Trading: The core philosophy advocated – owning individual stocks for compounding gains rather than frequent trading.
• Fallacy of Trading: The idea that attempting to time the market and profit from short-term fluctuations is generally unsuccessful.
• Valuation (P/E Ratio): A key metric for identifying undervalued companies with potential for growth.
• Data Center Demand: The significant and growing need for memory chips and hard drives driving growth in related companies.
• Mergers & Acquisitions (M&A): Anticipated increase in M&A activity as a positive catalyst for stock performance.
• Cyclical Analysis: Utilizing market cycles to identify potential buying opportunities.
• Undervaluation: Identifying companies trading below their intrinsic value based on earnings and growth potential.

I. Introduction & 2026 Game Plan

Jim Kramer outlines his investment strategy for 2026, emphasizing long-term ownership of individual stocks over short-term trading. He advocates for maximizing self-management of investments, utilizing index funds as a base, and focusing on the power of compounding. He stresses the importance of resisting the urge to sell during market dips, as this is where many investors falter ("Buy, SELL, BUY, SELL. STOP IT."). Kramer’s approach is rooted in his 20 years of experience in sales and trading. He promotes his book, How to Make Money in Any Market, as a guide to understanding market dynamics.

II. Venezuela & Speculative Trading

The program begins with a discussion of the political situation in Venezuela following President Trump’s actions regarding President Maduro. While acknowledging the newsworthiness of the event, Kramer cautions against chasing short-term profits from speculative trades based on it. He points out that the potential gains may already be priced into stocks like Chevron (Venezuelan interests, currently pumping 100,000 barrels/day) and US refiners (Valero, Philips 66, Marathon Petroleum) who could benefit from increased access to Venezuela’s heavy crude oil (900,000 barrels/day total production, much going to China – $50 billion debt). He warns that the infrastructure is dilapidated and rebuilding will be a lengthy process, potentially mirroring the difficulties experienced in Iraq. He argues that the initial stock surges were overblown, as investors paid a premium for potential gains that are years away. He cites the Iraq experience (9 years to double production to 4 million barrels/day) as a cautionary tale.

III. Focus on Value & Bank Stocks

Kramer shifts the focus to identifying undervalued opportunities. He suggests focusing on stocks that haven’t experienced significant gains, specifically highlighting bank stocks (Child Trust, JP Morgan, Citigroup) as currently cheap relative to the market. He anticipates a year of mergers and acquisitions, positioning Goldman Sachs as a key beneficiary due to its strong M&A and IPO involvement (currently trading at 17x earnings). Citigroup is also highlighted as undervalued (12x earnings) with potential for a “resurrection.” Capital One (12x earnings) is presented as a particularly attractive option, especially given its recent acquisition of Discover and potential benefits from anticipated interest rate cuts.

IV. Identifying Opportunities: Drug Stocks & Beyond

Kramer suggests looking for opportunities in sectors that have experienced recent declines. He points to pharmaceutical stocks, specifically Johnson & Johnson, which is spinning off its orthopedic business (deploy synthesis) to increase valuation, similar to the successful spin-off of Kenvue. He notes a temporary dip in J&J’s stock price as a potential entry point. He emphasizes the importance of the Price-to-Earnings (P/E) ratio as a key indicator of value, referencing its detailed explanation in his book.

V. Callers & Stock Specific Analysis

• ServiceNow: Caller inquiry – Kramer views it as currently overvalued at 42x earnings, despite being a good company, due to competition from hardware companies.
• Palantir: Caller praise and endorsement – Kramer remains bullish, citing its rapid growth and strong position.
• AppLovin: Kramer recommends buying, highlighting its dominance in mobile advertising and strong growth metrics (revenue tripled in 4 years).
• Deckers (Uggs): Kramer acknowledges recent struggles but suggests a potential buying opportunity based on Larry Williams’ technical analysis.
• Costco: Despite recent underperformance, Kramer, guided by Larry Williams’ cyclical analysis, suggests Costco is poised for a rally, citing undervaluation and strong fundamentals. He highlights the importance of the company’s shopping experience.
• Nvidia: Kramer defends Nvidia, urging investors to hold despite bearish sentiment.

VI. 2025 Market Review: Best & Worst Performers (S&P 500 & NASDAQ 100)

Kramer analyzes the best and worst performing stocks of 2025 in both the S&P 500 and NASDAQ 100.

• S&P 500 Winners: Dominated by data storage and memory companies (SanDisk, Western Digital, Micron, Seagate) driven by data center demand and AI development. Robinhood Markets also performed well, benefiting from speculative trading.
• S&P 500 Losers: Trade Desk (digital advertising), Pfizer (payment processor), Alexandria Real Estate (office space for life sciences), Deckers (footwear), Gardner (tech research).
• NASDAQ 100 Winners: Similar to S&P 500, with memory companies leading the way. IMSED (biopharmaceutical) and Palantir also showed strong gains.
• NASDAQ 100 Losers: Strategy (Bitcoin Treasury), Charter Communications (cable), Atlassian (collaboration software), Copart (salvage vehicles), PayPal (payment processing).

He emphasizes that the memory chip sector’s boom may be different this time due to the immense demand from data centers. He cautions against chasing past performance and advocates for taking profits ("snitle").

VII. The Persistent Pessimism & Investing Philosophy

Kramer criticizes the prevalence of pessimistic market commentary, even when proven wrong. He contrasts this with his focus on identifying undervalued American companies and allowing compounding to drive returns. He criticizes passive investing (index funds) as lacking conviction and failing to capitalize on opportunities. He emphasizes the importance of active research, observation, and a belief in American businesses. He highlights the success of the CNBC Investing Club in identifying Nvidia as a winning investment.

VIII. Conclusion

Kramer concludes by reiterating his 2026 game plan: focus on undervalued companies, prioritize long-term ownership, and resist the urge to trade based on short-term market fluctuations. He emphasizes the importance of independent research and a belief in the potential of American businesses. He encourages viewers to learn more through his book and CNBC resources.

Notable Quotes:

• “My job is not just to entertain you, but to educate, to teach you.” – Jim Kramer (Introduction)
• “Buy, SELL, BUY, SELL. STOP IT.” – Jim Kramer (On the dangers of frequent trading)
• “The fallacy of trading and the greatness of owning.” – Jim Kramer (Summarizing his investment philosophy)
• “If you can get the stock of a terrific company at a discount, not a premium… then you’re investing well instead of trading badly.” – Jim Kramer (On value investing)
• “There’s always a bull market somewhere.” – Jim Kramer (Concluding statement)

Technical Terms:

• P/E Ratio (Price-to-Earnings Ratio): A valuation metric comparing a company’s stock price to its earnings per share.
• Heavy Crude: A type of crude oil with low density and high viscosity.
• Spin-off: The creation of a new, independent company from a division of a parent company.
• M&A (Mergers & Acquisitions): The consolidation of companies through mergers or acquisitions.
• Cyclical Analysis: Analyzing market trends based on recurring patterns and cycles.
• Undervaluation: A situation where a stock’s price is below its intrinsic value.
• Par Value: A stock price of $100.
• IPO (Initial Public Offering): The first sale of stock by a private company to the public.
• Orphan Drugs: Drugs developed to treat rare diseases.
• Proprietary: Information or technology owned by a company and not available to the public.
• Leverage: Using borrowed money to increase potential returns (and risks).

This summary aims to provide a detailed and specific overview of the content presented in the YouTube video transcript, maintaining the original language and technical precision.